Malignant Infratentorial Neoplasm — Trials

Malignant Infratentorial Neoplasm — Trials · CancerIndex

Clinical trials

Registered studies

302 studies whose conditions map to this entity or one of its descendants. Status and phase are as posted on ClinicalTrials.gov. 50 studies per page.

Active: 99
Recruiting: 50
Ph III recruiting: 3
Growth YoY: —
Industry share: 9%
Top sponsor: National Cancer Institute (NCI)
Termination share: 37.3%

Computedformula ci-trial-intel-v1 · interventional studies · entity + NCIt descendants · hover a figure for its formulaCompare cancers Terminated studies (46)

clinicaltrialsPublishedShowing 1–17 of 17 studies matching the filters · status and phase as posted by the registrant; each row links to the study record.

NCT	Title	Status	Phase	Enrollment (n)	Sponsor	Countries	Last update	Source
NCT03173950	Immune Checkpoint Inhibitor Nivolumab in People With Recurrent Select Rare CNS Cancers	terminated	Phase 2	136	National Cancer Institute (NCI)NIH	1	Aug 18, 2026	clinicaltrials
NCT03904862	Testing the Safety and Tolerability of CX-4945 in Patients With Recurrent Medulloblastoma Who May or May Not Have Surgery	terminated	Phase 1 / Phase 2	21	Pediatric Brain Tumor ConsortiumNETWORK	1	Oct 30, 2025	clinicaltrials